Abstract
Background: Chronic Myeloid Leukaemia (CML) is associated with the BCRABL1 gene, which plays a central role in the pathogenesis of CML. Thus, it is crucial to suppress the expression of BCR-ABL1 in the treatment of CML. MicroRNA is known to be a gene expression regulator and is thus a good candidate for molecularly targeted therapy for CML.
Objective: This study aims to identify the microRNAs from edible plants targeting the 3’ Untranslated Region (3’UTR) of BCR-ABL1.
Methods: In this in silico analysis, the sequence of 3’UTR of BCR-ABL1 was obtained from Ensembl Genome Browser. PsRNATarget Analysis Server and MicroRNA Target Prediction (miRTar) Server were used to identify miRNAs that have binding conformity with 3’UTR of BCR-ABL1. The MiRBase database was used to validate the species of plants expressing the miRNAs. The RNAfold web server and RNA COMPOSER were used for secondary and tertiary structure prediction, respectively.
Results: In silico analyses revealed that cpa-miR8154, csi-miR3952, gma-miR4414-5p, mdm-miR482c, osa-miR1858a and osa-miR1858b show binding conformity with strong molecular interaction towards 3’UTR region of BCR-ABL1. However, only cpa-miR- 8154, osa-miR-1858a and osa-miR-1858b showed good target site accessibility.
Conclusion: It is predicted that these microRNAs post-transcriptionally inhibit the BCRABL1 gene and thus could be a potential molecular targeted therapy for CML. However, further studies involving in vitro, in vivo and functional analyses need to be carried out to determine the ability of these miRNAs to form the basis for targeted therapy for CML.
Keywords: BCR-ABL1, Chronic Myeloid Leukemia, MicroRNA, 3’ Untranslated Region, in silico, cross kingdom.
Graphical Abstract
[http://dx.doi.org/10.1111/j.1349-7006.2012.02346.x ] [PMID: 22632137]
[http://dx.doi.org/10.1016/j.beha.2009.04.002 ] [PMID: 19698927]
[PMID: 6245823]
[http://dx.doi.org/10.7326/0003-4819-145-12-200612190-00008 ] [PMID: 17179059]
[http://dx.doi.org/10.1056/NEJMoa062867 ] [PMID: 17151364]
[http://dx.doi.org/10.1007/s12253-016-0101-6 ] [PMID: 27590333]
[http://dx.doi.org/10.3324/haematol.2013.097675 ] [PMID: 24584347]
[http://dx.doi.org/10.1038/nrg3965 ] [PMID: 26077373]
[http://dx.doi.org/10.3390/ijms18010009] [PMID: 28025496]
[http://dx.doi.org/10.1186/s12864-017-3502-3 ] [PMID: 28361700]
[http://dx.doi.org/10.1186/s12918-016-0292-1 ] [PMID: 27502923]
[http://dx.doi.org/10.1038/cr.2016.13 ] [PMID: 26794868]
[http://dx.doi.org/10.3390/molecules19021568 ] [PMID: 24473213]
[http://dx.doi.org/10.1002/mnfr.201500137 ] [PMID: 26147655]
[http://dx.doi.org/10.1093/nar/gkx1098 ] [PMID: 29155950]
[http://dx.doi.org/10.1093/nar/gky316 ] [PMID: 29718424]
[http://dx.doi.org/10.1093/nar/gky1141 ] [PMID: 30423142]
[http://dx.doi.org/10.1186/1471-2105-12-300 ] [PMID: 21791068]
[http://dx.doi.org/10.1186/1748-7188-6-26 ] [PMID: 22115189]
[http://dx.doi.org/10.1007/978-1-4939-6433-8_13 ] [PMID: 27665601]
[http://dx.doi.org/10.1371/journal.pone.0061858] [PMID: 23613955]
[http://dx.doi.org/10.1038/srep12460 ] [PMID: 26228085]
[http://dx.doi.org/10.1182/blood.V114.22.854.854]
[http://dx.doi.org/10.1073/pnas.1121356109 ] [PMID: 22496592]
[http://dx.doi.org/10.1089/dna.2006.0545 ] [PMID: 17465887]
[http://dx.doi.org/10.1093/nar/gkq768 ] [PMID: 20805242]
[http://dx.doi.org/10.1093/nar/gkj077 ] [PMID: 16381968]
[http://dx.doi.org/10.3390/ijms19072007] [PMID: 29996470]
[http://dx.doi.org/10.1038/cr.2011.158 ] [PMID: 21931358 ]